Recro Pharma (NASDAQ: REPH) is a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of acute post operative pain. Recro Pharma is currently developing IV/IM Meloxicam, a proprietary, Phase III-ready, rapid-onset, long-acting preferential COX-2 inhibitor, and Dex-IN, a proprietary intranasal formulation of dexmedetomidine in Phase II, both for the treatment of acute post operative pain. As Recro Pharma's product candidates are not in the opioid class of drugs, the Company believes its candidates would avoid many of the side effects associated with commonly prescribed opioid therapeutics, such as addiction, constipation and respiratory distress while maintaining analgesic effect. Recro Pharma owns and operates an 97,000 square foot, DEA-licensed facility that manufactures five commercial products that are commercialized by partners and receives royalties associated with the sales of these products. Source
No articles found.
St. Renatus, LLC, named after the patron saint of anesthesia, is a privately held ...
St. Renatus, LLC, named after the patron saint ...
Alpine is a development-stage specialty pharmaceutical company focused on discover...
Alpine is a development-stage specialty pharmac...
At GlycoMimetics, we are committed to helping to make a difference in the lives of...
At GlycoMimetics, we are committed to helping t...
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-base...
Takeda Pharmaceutical Company Limited (TSE:4502...
Founded in 2006 and headquartered in San Diego, Adamis (ADMP) is a specialty bioph...
Founded in 2006 and headquartered in San Diego,...
MEI Pharma (Nasdaq: MEIP) is a San Diego-based late-stage pharmaceutical company f...
MEI Pharma (Nasdaq: MEIP) is a San Diego-based ...
NuvectraÂŽ is a neurostimulation company committed to helping physicians improve t...
NuvectraÂŽ is a neurostimulation company commit...
Join the National Investor Network and get the latest information with your interests in mind.